AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04959123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacokinetic analysis
Description: Non-compartmental descriptive pharmacokinetic analysis (i.e. without the need for mathematical modelling), with determination of the pharmacokinetic parameters of interest either directly from the experimental points (Cmax, Tmax), or from simple mathematical equations (calculation of the area under the curve (AUC) by the trapezoidal method, calculation of the terminal slope of elimination)
Study NCT06130332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 with chemotherapy
Description: Tirellizumab+Carboplatin+albumin-bound paclitaxel:2 courses Tirellizumab,+Carboplatin+albumin-bound paclitaxel Tirellizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Tirellizumab, Carboplatin, albumin-bound paclitaxel:2 cycles Surgery：Enlarged local excision，excision with the safe margin 1.0-1.5cm away from the original tumor
Study NCT06130332 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: upright surgery
Description: Surgery：Primary resection，excision with the safe margin 1.0-1.5cm away from the original tumor~selective neck dissection:I II III region neck dissection
Study NCT05995535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX/PGB
Description: lofexidine tablets 0.18mg tabs~pregabalin capsules 100mg and 25mg
Study NCT05995535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LFX/PGB
Description: lofexidine tablets 0.18mg tabs~pregabalin capsules 100mg and 25mg
Study NCT05995535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX/PLA-PGB
Description: lofexidine tablets 0.18mg tabs~pregabalin capsules 0mg
Study NCT05995535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LFX/PLA-PGB
Description: lofexidine tablets 0.18mg tabs~pregabalin capsules 0mg
Study NCT05543590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: 5 sessions of plasma exchanges
Study NCT05543590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Blood collection to assess biological markers at baseline, M3 and M12
Study NCT05543590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection to assess biological markers at baseline, M3 and M12
Study NCT05543590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stool samples
Description: Stool samples will be collected from participants at baseline,M3 and M12
Study NCT05543590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool samples
Description: Stool samples will be collected from participants at baseline,M3 and M12
Study NCT05543590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PET scan
Description: PET scan at baseline and M6
Study NCT05543590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET scan
Description: PET scan at baseline and M6
Study NCT05543590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cycle ergometer stress test
Description: Cycle ergometer stress test at M6
Study NCT05543590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometer stress test
Description: Cycle ergometer stress test at M6
Study NCT05543590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires at baseline
Description: Questionnaires at baseline, M3 and M6
Study NCT05543590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires at baseline
Description: Questionnaires at baseline, M3 and M6
Study NCT05543590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medical consultations
Description: Medical consultations
Study NCT05173129 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Posture Analysis
Description: Posture analysis and assessment of mechanical properties of posture muscles
Study NCT05165498 — intervention group
Intervention type: PROCEDURE
Intervention: Real-time ultrasound guidance for thoracic epidural catheter placement.
Description: With an US-guided parasagittal oblique approach, the interlaminar space at the union between laminas and spinous processes at the predefined insertion level will be identified. A skin wheal will be raised with 3 mL of lidocaine 1%. Afterward, an 18-gauge Tuohy epidural block needle will be advanced under direct US vision until the tip is insinuated between the laminas and anchored to the flavum ligament. Then the needle will be attached to a low resistance syringe prefilled with saline solution and advanced until LOR to injection is confirmed. Then a 20-Gauge epidural catheter will be inserted 3-5 cm beyond the needle tip inside the epidural space and the needle removed.
Study NCT05173129 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Posture Analysis
Description: Posture analysis and assessment of mechanical properties of posture muscles
Study NCT06485999 — intervention group
Intervention type: PROCEDURE
Intervention: Biologically Oriented Preparation Technique
Description: It is a preparation technique without a finish line, also known as the biologically oriented preparation technique (BOPT). In this protocol, the crown's anatomic emergence profile at the cementoenamel junction (CEJ) is eliminated with diamond rotary instruments to create a new prosthetic junction, adapted to the gingival margin. The aim of this protocol is to create a new anatomic crown with a prosthetic emergence profile that simulates the shape of the natural tooth.
Study NCT05038657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Treatment will consist of atezolizumab, by IV infusion, at a fixed dose of 1680 mg, every 28 days (day 1 of each cycle, +/- 3 days), for up to one year. Each participant will receive up to 13 doses in total.
Study NCT05746897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM1F Injection
Description: This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period.
Study NCT05746897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab injection
Description: This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period.
Study NCT06221657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemlidy
Description: 1 tablet once a day, oral administration
Study NCT06221657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Virreal
Description: 1 tablet once a day, oral administration
Study NCT05428878 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ANS Watch
Description: 1. ANS Watch will be used to record the pulse waves~2. Constitution questionnaire will be used to measure the constitution type
Study NCT05973370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
Study NCT05973370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA) 500 mg
Description: All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an addon treatment to the current DMARDs treatments for rheumatoid arthritis.
Study NCT05904626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELGN-2112
Description: To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.
Study NCT05904626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo formulation consisting of the same inactive ingredients as ELGN-2112.
Study NCT05655117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI based eye screening
Description: The application of AI devices i.e Fundus Camera to detect diabetic retinopathy and macular Oedema in diabetics at the primary care centre
Study NCT06071312 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: single FMT
Description: This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through a single infusion of FMT
Study NCT06071312 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sequential FMT
Description: This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through multiple infusions of FMT (sequential approach)
Study NCT04901572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: QISI device
Description: QISI device will simulate its use in ICSI procedures and evaluate sperm cells according to WHO guidelines.
Study NCT05689619 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silibinin
Description: Silibinin 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
Study NCT05689619 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
Study NCT05900440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound with Artificial Inteligence Engabled
Description: Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
Study NCT05900440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound without Artificial Intelligence Enabled
Description: Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
Study NCT05981976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Specified dose on specified days
Study NCT05501626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Theta Burst Stimulation (TBS)
Description: Each session will be comprised of ACTIVE TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
Study NCT05501626 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Theta Burst Stimulation (TBS)
Description: Each session will be comprised of SHAM TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
Study NCT05769231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia in Chatbot
Description: Digital interventions can relieve the worldwide burden of mental disorders. The low set-up costs and barriers of online platforms make digital interventions very cost-effective. By using the Internet as a delivery medium, many people can enjoy unrestricted access to self-help information. Unlike traditional face-to-face intervention, the effects of digital self-help interventions are scalable. The current study attempts to extend the boundary of digital interventions from accommodating didactic and informational content to providing interactive, intelligent, and most importantly, patient-centered conversational agents. AI chatbots can provide suitable recommendations and training materials to users according to their behavioral, mental, and motivational readiness. Since existing AI chatbots are developed for Western societies, a culture-specific Chinese chatbot will fill the research and service gaps.
Study NCT05796479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab DP1
Description: Injection solution 1~Subcutaneous
Study NCT05796479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab DP2
Description: Injection solution 2~Subcutaneous
Study NCT05533567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: The experimental group was sedated with remimazolam.
Study NCT05533567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The control group was sedated with propofol.
Study NCT06283186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise with lower limb cycle ergometer
Study NCT06283186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise with upper limb cycle ergometer
Study NCT06069661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortic Stenosis
Description: F2 Filter and Delivery system to cover the 3 great cerebral vessels
Study NCT05177055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based light therapy at gradually advanced timing for DSWPD
Description: Light therapy at gradually advanced timing, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques
Study NCT05177055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based light therapy at gradually advanced timing for DSWPD and additive bb-glasses
Description: Light therapy (LT) at gradually advanced timing, bb-glasses 12 hrs after LT, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques
Study NCT05177055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-week wait list for sleep-school
Description: Treatment as usual in a psychiatric outpatient clinic
Study NCT05447702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Intravenous (IV) infusion
Study NCT05447702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: po.
Study NCT05447702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV infusion.
Study NCT05447702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: IV infusion.
Study NCT05447702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV infusion.
Study NCT05432531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti JAK1,2
Description: Induction of remission of active lupus nephritis
Study NCT05432531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamid
Description: Induction of remission of active lupus nephritis
Study NCT04924426 — intervention group
Intervention type: PROCEDURE
Intervention: TTC immersion
Description: TTC immersion
Study NCT05057364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Smart Virtual Self-Management Group
Description: The Heart Smart Intervention is a 6 week virtual program consisting of one individual technology training session followed by 5 one hour group education sessions.
Study NCT04825054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with NAVA mode
Description: To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
Study NCT04825054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with PCV mode
Description: To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
Study NCT04825054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with PSV mode
Description: To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
Study NCT06487013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArcBlate Focused Ultrasound Ablation System
Description: MR-guided High Intensity Focused Ultrasound (MRgHIFU)
Study NCT06487013 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham MRgHIFU treatment
Description: Sham MRgHIFU treatment
Study NCT06302257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorprocaine
Description: we aim to examine whether selective nociceptive analgesia can be obtained in epidural analgesia for women in labor by using a combination of lidocaine (opens TPRV-1 and TPRA-1 channels) and chlorprocaine (polarized local anesthetic)
Study NCT06302257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Study participants will receive lidocaine alone
Study NCT06302257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine-chlorprocaine combination
Description: study participants randomized to this study arm will receive a a 50:50 mixture of both drugs - where all drugs are administered in concentrations based on their ED50 doses, together with epidural opioids (fentanyl)
Study NCT05850494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HFA MDI
Description: * Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA
Study NCT04902235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: CRH administration
Description: CRH at 1.0 µg/kg/body weight will be injected intravenously as a bolus over 30 seconds and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after CRH:placebo administration to assess OT secretory patterns
Study NCT04902235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control: Placebo administration
Description: Sodium Chloride 0.9% will be administered intravenously as a bolus over 30 seconds at equivalent volume than CRH administration (1.0 µg/kg/body weight)
Study NCT05850494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFO MDI
Description: * Dose formulation: MDI~* Unit dose strength(s): Experimental (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA
Study NCT06046742 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M1-c6v1
Description: Intravenous drip administration
Study NCT05330884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: 0.1ml BCg vaccine to be given intradermally
Study NCT05330884 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral Chemoprophylaxis
Description: Oral chemoprophylaxis will be standard of care - either 6 months of Isoniazid or 3 months of weekly Isoniazid and Rifapentine
Study NCT06272227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alfacalcidol
Description: Subjects assigned to arm 1 take two doses of alfacalcidol once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).
Study NCT06272227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects assigned to arm 2 take two doses of placebo once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).
Study NCT06272227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: denosumab
Study NCT06272227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Denosumab
Description: denosumab